{"schema_version":"secwatch.filing_event.v1","accession":"0001599298-24-000113","form_type":"8-K","ticker":"SMMT","cik":"0001599298","company_name":"Summit Therapeutics Inc.","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.709380+00:00","generated_at":"2026-05-31T12:17:03.908848+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Summit Therapeutics Q2 net loss $60.4M; ivonescimab achieves first Phase III win over Keytruda","bullets":["GAAP net loss $60.4M ($0.09/sh) vs $14.7M ($0.02) in Q2 2023; non-GAAP loss $34.3M.","Cash $325.8M (up from $186.2M) after $200M June equity offering; runway into Q4 2025.","HARMONi-2: ivonescimab monotherapy beat pembrolizumab in 1L NSCLC, first drug to do so in Phase III.","HARMONi-A: ivonescimab+chemo reduced progression/death by 54% (HR 0.46) in EGFR-mutated NSCLC post-TKI.","Expanded license to Latin America, Middle East, Africa; five-year strategic collaboration with MD Anderson."],"urls":{"canonical":"https://secwatch.observer/filing/0001599298-24-000113","json":"https://secwatch.observer/filing/0001599298-24-000113.json","markdown":"https://secwatch.observer/filing/0001599298-24-000113.md","text":"https://secwatch.observer/filing/0001599298-24-000113.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1599298/000159929824000113/0001599298-24-000113-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1599298/000159929824000113/smmt-20240806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:17:03.908848+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}